Concepedia

Author

Ivana N. Micallef

Mayo ClinicORCID

Also Known As

I Micallef, I N M Micallef, I N Micallef, I. Micallef, I. N Micallef, I. N. M. Micallef, I. N. Micallef, I.N. Micallef, I.N.M. Micallef, Ivana Micallef

383

Publications

12.4K

Citations

58

H-Index

89

Concepts

All Affiliations

Mayo ClinicMayo Clinic in ArizonaMayo Clinic in FloridaWinnMedWashington University in St. Louis
IN

About

Ivana N. Micallef is an author at Mayo Clinic specializing in medicine, immunology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

36

65

3.5K

2

Health Sciences

17

22

903

3

Public Health

2

2

131

4

Engineering

1

1

14

5

Biomedical Engineering

1

1

14

Ivana N. Micallef

×

147

Publications

11.4K

Citations

56

H-Index

YearCitations

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee,

Blood

2009

773

Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma

John F. DiPersio, Ivana N. Micallef, Patrick J. Stiff,

Journal of Clinical Oncology

2009

670

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Wei Ding, Betsy LaPlant, Timothy G. Call,

Blood

2017

411

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais,

Journal of Clinical Oncology

2014

399

Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study

Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon,

Journal of Clinical Oncology

2014

362

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

Angela Dispenzieri, Morie A. Gertz, Robert A. Kyle,

Blood

2004

318

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Thomas E. Witzig, Craig B. Reeder, Betsy LaPlant,

Leukemia

2010

298

Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma

Luis F. Porrata, Morie A. Gertz, David J. Inwards,

Blood

2001

266

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

Angela Dispenzieri, Robert A. Kyle, Martha Q. Lacy,

Blood

2004

241

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

Patrick B. Johnston, David J. Inwards, Joseph P. Colgan,

American Journal of Hematology

2010

219

Page 1